

# Contents

<b>Abbreviations</b>	xv
<b>1. Introduction</b>	<b>1</b>
<b>2. General</b>	<b>4</b>
2.1 Current directions	4
2.1.1 Strategic directions in biological standardization: WHO priorities	4
2.1.2 Blood products and related in vitro diagnostics: recent and planned activities in biological standardization	5
2.1.3 Vaccines and biotherapeutics: recent and planned activities in biological standardization	7
2.2 Reports	9
2.2.1 Report from the WHO Blood Regulators Network	9
2.2.2 Report of the fifth meeting of WHO collaborating centres to support the development of WHO biological reference preparations for in vitro diagnostic devices	10
2.2.3 Report from the network of WHOCCs for the standardization and evaluation of vaccines	12
2.2.4 Report of a WHO informal consultation on international standards for biotherapeutic products	13
2.3 Feedback from custodian laboratories	15
2.3.1 Developments and scientific issues highlighted by custodians of WHO biological reference preparations	15
2.4 Cross-cutting activities of other WHO committees and groups	21
2.4.1 Update on matters arising from the International Nonproprietary Names Expert Group	21
2.4.2 Collaborative procedure for facilitating national registration of WHO prequalified medicinal products	22
2.4.3 Proposal to transition from microbiological to physicochemical assays for antibiotic potency testing	23
2.4.4 Labelling information for influenza vaccines intended for use in pregnant women	25
2.4.5 Influenza vaccine response during the start of a pandemic	26
<b>3. International Recommendations, Guidelines and other matters related to the manufacture and quality control of biological substances</b>	<b>28</b>
3.1 General	28
3.1.1 WHO good manufacturing practices for biological products	28
3.1.2 Update on the development of a candidate control material for adventitious virus detection using deep sequencing	29
3.2 Biotherapeutics other than blood products	30
3.2.1 Regulatory assessment of approved rDNA-derived biotherapeutics	30
3.3 Blood products and related substances	31
3.3.1 Ebola-related issues	31
3.3.2 Local production of blood products	32
3.3.3 Residual risk of virus infections caused by blood products	33
3.3.4 WHO general assessment tool for conducting gap analysis of national regulatory systems for health products and technologies	34



8.1.2	First WHO international standards for meningococcal serogroups A and X polysaccharide	78
8.1.3	Third WHO International Standard for diphtheria toxoid for use in flocculation test	79
8.2	Proposed new projects and updates - vaccines and related substances	80
8.2.1	Proposed First WHO international standards for meningococcal serogroups W and Y polysaccharide	80
8.2.2	Proposed First WHO international standards for Vi polysaccharide	81
8.2.3	Proposed First WHO International Standard for anti-Vi polysaccharide serum (human)	82
8.2.4	Proposed First WHO Reference Panel for non-typhoidal salmonella O-antigen polysaccharides	82
8.2.5	Proposed First WHO international standards for antibodies (human) to <i>Salmonella enterica</i> serovar Typhimurium (04,5 LPS) and Enteritidis (09 LPS)	83
8.2.6	Proposed First WHO International Standard for <i>Salmonella enterica</i> serovar Paratyphi A 02 polysaccharide	83
8.2.7	Proposed First WHO International Standard for antibodies (human) to <i>Salmonella enterica</i> Paratyphi A 02 polysaccharide	84
8.2.8	Proposed First WHO Reference Panel for O-antigen polysaccharides for <i>Shigella</i> strains	84
8.2.9	Proposed First WHO Reference Panel for anti- <i>Shigella</i> O-antigen polysaccharide serum (human)	85
8.2.10	Proposed First WHO International Standard for anti- <i>Clostridium difficile</i> serum (human)	86

## Annex 1

WHO Recommendations, Guidelines and other documents related to the manufacture and quality control of biological substances used in medicine	87
--	----

## Annex 2

WHO good manufacturing practices for biological products	
Replacement of Annex 1 of WHO Technical Report Series, No. 822	93

## Annex 3

Regulatory assessment of approved rDNA-derived biotherapeutics	
Addendum to Annex 4 of WHO Technical Report Series, No. 987	131

## Annex 4

Recommendations to assure the quality, safety and efficacy of recombinant human papillomavirus virus-like particle vaccines	
Replacement of Annex 1 of WHO Technical Report Series, No. 962	147

## Annex 5

Guidelines on the stability evaluation of vaccines for use under extended controlled temperature conditions	235
---	-----

## Annex 6

Biological substances: WHO International Standards, Reference Reagents and Reference Panels	265
---	-----